63. 特発性血小板減少性紫斑病 Idiopathic thrombocytopenic purpura Clinical trials / Disease details

臨床試験数 : 363 / 薬物数 : 212 - (DrugBank : 43) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 138

49 trials found

diseases per page:

Showing 1 to 10 of 49 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-004032-21-DK (EUCTR)	11/01/2022	16/04/2021	A Phase 3 study to evaluate the efficacy and safety of efgartigimod PH 20 Subcutaneous in adult pati ...	A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficac ...	Primary immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: LLT;Classification code 10083843;T ...	Product Name: efgartigimod PH20 SC INN or Proposed INN: efgartigimod alfa	argenx BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	156	Phase 3	Portugal;Serbia;United States;Taiwan;Greece;Spain;Thailand;Ireland;Israel;Chile;Russian Federation;C ...
2	NCT04812925 (ClinicalTrials.gov)	November 17, 2021	15/3/2021	A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patie ...	A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigi ...	Primary Immune Thrombocytopenia	Biological: efgartigimod PH20 SC	argenx	NULL	Recruiting	18 Years	N/A	All	156	Phase 3	United States;Australia;Japan;Russian Federation
3	EUCTR2020-004033-20-NO (EUCTR)	08/09/2021	20/04/2021	Study to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Pati ...	A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigi ...	Primary immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: LLT;Classification code 10083843;T ...	Product Name: efgartigimod PH20 SC INN or Proposed INN: efgartigimod alfa	argenx BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	156	Phase 3	Portugal;Serbia;United States;Taiwan;Greece;Spain;Thailand;Ireland;Israel;Chile;Russian Federation;C ...
4	EUCTR2020-004033-20-GR (EUCTR)	07/09/2021	19/07/2021	Study to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Pati ...	A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigi ...	Primary immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: LLT;Classification code 10083843;T ...	Product Name: efgartigimod PH20 SC INN or Proposed INN: efgartigimod alfa	argenx BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	156	Phase 3	Portugal;Serbia;United States;Taiwan;Greece;Spain;Thailand;Ireland;Israel;Chile;Russian Federation;C ...
5	EUCTR2020-004033-20-BG (EUCTR)	03/09/2021	26/05/2021	Study to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Pati ...	A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigi ...	Primary immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: LLT;Classification code 10083843;T ...	Product Name: efgartigimod PH20 SC INN or Proposed INN: efgartigimod alfa	argenx BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	156	Phase 3	Portugal;Serbia;United States;Taiwan;Greece;Spain;Thailand;Ireland;Israel;Chile;Russian Federation;C ...
6	EUCTR2020-004033-20-PT (EUCTR)	03/09/2021	20/05/2021	Study to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Pati ...	A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigi ...	Primary immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: LLT;Classification code 10083843;T ...	Product Name: efgartigimod PH20 SC INN or Proposed INN: efgartigimod alfa	argenx BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	156	Phase 3	Portugal;Serbia;United States;Taiwan;Greece;Spain;Thailand;Ireland;Israel;Chile;Russian Federation;C ...
7	EUCTR2020-004033-20-ES (EUCTR)	13/08/2021	09/06/2021	Study to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Pati ...	A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigi ...	Primary immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: LLT;Classification code 10083843;T ...	Product Name: efgartigimod PH20 SC INN or Proposed INN: efgartigimod alfa	argenx BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	156	Phase 3	Portugal;Serbia;United States;Taiwan;Greece;Spain;Thailand;Ireland;Israel;Chile;Russian Federation;C ...
8	EUCTR2020-004033-20-IT (EUCTR)	23/07/2021	17/08/2021	Study to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Pati ...	A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigi ...	Primary immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: LLT;Classification code 10083843;T ...	Product Name: efgartigimod PH20 SC Product Code: [ARGX-113] INN or Proposed INN: efgartigimod alfa	ARGENX BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	156	Phase 3	Portugal;Serbia;United States;Taiwan;Greece;Spain;Thailand;Ireland;Israel;Chile;Russian Federation;C ...
9	EUCTR2020-004032-21-PT (EUCTR)	19/07/2021	11/03/2021	A Phase 3 study to evaluate the efficacy and safety of efgartigimod PH 20 Subcutaneous in adult pati ...	A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficac ...	Primary immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: LLT;Classification code 10083843;T ...	Product Name: efgartigimod PH20 SC INN or Proposed INN: efgartigimod alfa	argenx BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	156	Phase 3	Portugal;Serbia;United States;Taiwan;Greece;Spain;Thailand;Ireland;Israel;Chile;Russian Federation;C ...
10	EUCTR2020-004032-21-NO (EUCTR)	25/06/2021	18/03/2021	A Phase 3 study to evaluate the efficacy and safety of efgartigimod PH 20 Subcutaneous in adult pati ...	A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficac ...	Primary immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: LLT;Classification code 10083843;T ...	Product Name: efgartigimod PH20 SC INN or Proposed INN: efgartigimod alfa	argenx BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	156	Phase 3	United States;Serbia;Portugal;Taiwan;Greece;Thailand;Spain;Ireland;Russian Federation;Chile;Israel;C ...

First Previous1 2 3 4 5Next Last